Neurocrine Biosciences target price raised to $215 from $210 by Piper Sandler
NBIX•Piper Sandler raised its target price for Neurocrine Biosciences to $215 from $210.
Related News
JPMorgan raises Tempus AI target price to $80 from $70
TEM•
Palantir Technologies raises target price to $235 from $231
PLTR•
Bright Minds Biosciences: Piper Sandler cuts target price to $115 from $220
DRUG•
Principal Financial Group target price cut to $105 from $106
PFG•
Once Upon a Farm cut to underperform from buy; price objective lowered to $10 from $21
OFRM•